Analystreport

Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock.

Bellicum Pharmaceuticals, Inc.  (BLCM) 
Last bellicum pharmaceuticals, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.bellicum.com/investor-overview